Close
Nordic 9Nordic 9

Cancer Research Horizons (investor - Corporate Investor)

United Kingdom cancerresearchhorizons.com
See something wrong or missing? Let us know
Offices:London

Cancer Research Horizons is a British specialist drug discovery, development and commercialisation company

Average round investment:29.7M USD
Average number per year:1.7
Distribution: 2025 (2)2024 (2)2023 (1)
Portfolio companies: Netherlands Laigo BioUnited Kingdom TrogenixUnited Kingdom 52 North Health See the entire list
Mostly invests in: United Kingdom United Kingdom (4) Health services (5)
See the entire list

Showing 3 of 5 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Cancer Research Horizons

Name Criteria
United States What If Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Health services, Pharma, Software Services, Biotech, Hardware
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Netherlands Unilever Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United Kingdom ⌘ Cmd + N
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Software Services, Hardware
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States HG Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Software Services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.4
  • Active last 12 months: Yes
Finland Mandatum Asset Management
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Software Services, Hardware
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.4
  • Active last 12 months: Yes
United States A.Capital Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Software Services, Hardware
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United Kingdom Jim O’Neill
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Pharma, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
United States Shasta Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Health services, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Germany PS Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Health services, Pharma, Software Services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States InterAlpen Partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Manufacturing, Software Services, Hardware
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Top